Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 10/20 10:14:59 pm
121.33 USD   -10.76%
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVE : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : to Announce Third Quarter 2017 Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 10:25am CEST

Release date- 03102017 -

SUMMIT, N.J. - Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results.

The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will also host a webcast of an investor event at the MSParis2017-7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene's management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company's web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Forward Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'plans,' 'will,' 'outlook' and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Contact:

Tel: 908-673-9969

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVERS : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
10/19 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/19 CELGENE : Patent Issued for Romidepsin Formulations and Uses (USPTO 9782451)
10/19 CELGENE CORPORATION (NASDAQ : CELG) Files An 8-K Costs Associated with Exit or D..
10/19 CELGENE CORP /DE/ : Costs Associated with Exit or Disposal Activities (form 8-K)
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19 CELGENE : Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Pro..
10/19 CELGENE : Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Mult..
More news
News from SeekingAlpha
10/20 Celgene selloff weighs on biotechs, IBB down 1%
10/20 Midday Gainers / Losers
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
10/20 Analyst weigh in on Celgene's flop in Crohn's with mongersen; shares down 10%
Financials ($)
Sales 2017 13 226 M
EBIT 2017 7 529 M
Net income 2017 4 508 M
Debt 2017 3 949 M
Yield 2017 -
P/E ratio 2017 21,68
P/E ratio 2018 16,66
EV / Sales 2017 7,48x
EV / Sales 2018 6,08x
Capitalization 94 923 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 149 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION18.51%94 923
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223